, Volume 69, Issue 8–9, pp 547–556 | Cite as

Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell “missing self” recognition

  • Karl-Johan MalmbergEmail author
  • Ebba Sohlberg
  • Jodie P. Goodridge
  • Hans-Gustaf Ljunggren
Open Access
Part of the following topical collections:
  1. Topical Collection on MHC/KIR in Health and Disease


The ability of NK cells to specifically recognize cells lacking expression of self-MHC class I molecules was discovered over 30 years ago. It provided the foundation for the “missing self” hypothesis. Research in the two past decades has contributed to a detailed understanding of the molecular mechanisms that determine the specificity and strength of NK cell-mediated “missing self” responses to tumor cells. However, in light of the recent remarkable breakthroughs in clinical cancer immunotherapy, the cytolytic potential of NK cells still remains largely untapped in clinical settings. There is abundant evidence demonstrating partial or complete loss of HLA class I expression in a wide spectrum of human tumor types. Such loss may result from immune selection of escape variants by tumor-specific CD8 T cells and has more recently also been linked to acquired resistance to checkpoint inhibition therapy. In the present review, we discuss the early predictions of the “missing self” hypothesis, its molecular basis and outline the potential for NK cell-based adoptive immunotherapy to convert checkpoint inhibitor therapy-resistant patients into clinical responders.


Natural killer (NK) cell Education Differentiation Killer cell immunoglobulin-like receptors (KIR) Missing self Tumor Leukemia MHC class I HLA Immune escape 

The “missing self” hypothesis and its predictions

More than half a century ago, it was observed that F1-hybrid mice (derived from a cross of two inbred strains) could reject bone marrow and tumor cell grafts of parental strain-origin (Cudkowicz and Stimpfling 1964). This “F1-hybrid-resistance” phenomenon contrasted with the common laws of transplantation, stating that graft rejection should only takes place if the bone marrow or tumor graft carried “transplantation antigens,” e.g., foreign major histocompatibility complex (MHC) class I antigens. In the F1-hybrid anti-parental setting, however, no such foreign antigens existed and the rejection remained a mystery until the discovery of NK cells in the mid-1970s (Kiessling et al. 1975). It turned out that the F1-hybrid-resistance phenomenon could be linked to these cells (Kiessling et al. 1977). The biology of NK cell-mediated F1-hybrid-resistance, and related phenomena, stimulated Klas Kärre to formulate the “missing self” hypothesis for NK cell recognition of target cells (Karre 2008; Karre et al. 1986; Ljunggren and Karre 1990). The hypothesis postulated that absence, or reduced expression, of “self” MHC class I molecules could suffice to render a target cell susceptible to killing by NK cells. Noteworthy, the model explained the “F1-hybrid-resistance” phenomenon. However, it required experimental verification to gain acceptance.

To more directly test the predictions of the “missing self” hypothesis, the strategy was taken to select MHC class I-deficient mutant cell lines from mutagenized MHC class I-expressing (NK cell-resistant) T cell lymphoma cell lines, and to test their susceptibility to NK cell lysis. As hypothesized, such MHC class I-negative mutants were rendered sensitive to NK cell lysis in vitro and were rejected upon inoculation in immunocompetent syngeneic C57BL/6 (B6) mice (Karre et al. 1986; Ljunggren and Karre 1985). Subsequent studies demonstrated that the rejection was dependent on NK cells, in line with the earlier predictions (Karre et al. 1986; Ljunggren and Karre 1985; Ljunggren et al. 1988a, b). Experiments in which MHC class I expression was restored in the mutant cell lines subsequently confirmed that the NK cell-sensitive phenotype of the mutant cell lines was linked directly to the loss of MHC class I expression (Glas et al. 1992; Ljunggren et al. 1989, 1990b).

Two lines of research further confirmed the notion of MHC class I interference with NK cell recognition of target cells. The first was through the generation of β2m-deficient mice, which made it possible to study NK cell recognition of normal (i.e., untransformed) cells lacking expression of MHC class I molecules. LPS- and Con A-induced blasts from these mice were found to be susceptible to lysis in vitro by NK cells from corresponding wild type mice, and MHC class I-deficient bone marrow grafts from these mice were rejected by wild-type mice in vivo (Hoglund et al. 1991; Liao et al. 1991). The second line of research was the identification of MHC class I-specific inhibitory receptors (Karlhofer et al. 1992; Moretta et al. 1994). The generation of monoclonal antibodies against these MHC class I-binding receptors on human and murine NK cells made it possible to test critical predictions of the “missing self” hypothesis (Ljunggren and Karre 1990). One key prediction was that an inhibitory receptor-blockade should lead to augmented killing of MHC class I expressing target cells, which indeed was observed (Karlhofer et al. 1992; Moretta et al. 1994).

While the identification of inhibitory receptors in part uncovered the molecular mechanisms used by NK cells to recognize MHC class I deficient tumor cells, later studies showed that sensing the absence of self-MHC class I molecules is not sufficient to cause target cell killing. NK cells also need stimulation by target cell ligands to trigger activation via specific receptors. The identity of the latter (Bauer et al. 1999; Pessino et al. 1998; Vitale et al. 1998) remained elusive until several years after the discovery of inhibitory receptors. We now know that NK cell recognition of tumor and bone marrow grafts is tightly regulated by processes involving the integration of signals delivered from multiple activating and inhibitory receptors (Lanier 2005). The nature and molecular specificity of the key inhibitory receptors are described in the following section.

The molecular basis for “missing self” reactivity

NK cell function, including the ability to sense “missing self” MHC class I molecules, is determined by the integrated signaling through multiple activating and inhibitory receptors (Bryceson et al. 2006; Lanier 2005). Mice and humans use two structurally unrelated receptor families; the Ly49 and KIR receptors, respectively, to recognize MHC class I molecules (Parham 2005b). Although the two receptor families have evolved independently, they share many features including a stochastic expression pattern and a central role in the formation of a functional diversification within the NK cell repertoire (Parham 2008).

The human KIR gene cluster is located within the leukocyte receptor complex on chromosome 19 (Wende et al. 1999) and displays an extensive diversity between individuals. Generally, KIR haplotypes contain between 9 and 17 genes (15 genes according to the most recent update of the nomenclature (Personal communication, Steven Marsh, Anthony Nolan Research Institute, UK) (Uhrberg et al. 1997, 2002), although studies of gene copy number variations have revealed a KIR haplotype with only four genes (Traherne et al. 2010). Additionally, KIR genes contain variable sites, which result in multi-allelic polymorphism (Gardiner et al. 2001; Shilling et al. 2002; Uhrberg et al. 1997; Wagtmann et al. 1995). Hence, it is very unlikely that two randomly selected individuals share the same KIR genotype (Shilling et al. 2002).

Four major inhibitory KIRs have been identified (KIR2DL2/3, KIR2DL1, KIR3DL1, and KIR3DL2) that recognize polymorphic residues within the α1 and α2 domains of the HLA class I heavy chain. KIR2DL2/3 recognize HLA-C allotypes with asparagine 80 (C1), KIR2DL1 recognizes HLA-C allotypes with lysine 80 (C2), KIR3DL1 recognizes HLA-A and HLA-B allotypes with Bw4 motifs at positions 77–83, and KIR3DL2 recognizes HLA-A3/11 and HLA-F (Goodridge et al. 2013; Parham 2005a). The activating receptors KIR2DS1, KIR2DS2, and KIR3DS1 display similar extracellular domains as their inhibitory counterparts and are thus thought to share binding specificities. KIR2DS1 and KIR2DS2 have shown to weakly bind to HLA-C2 and HLA-C1, respectively (Biassoni et al. 1997; Stewart et al. 2005); however, interaction between KIR3DS1 and Bw4 has not been confirmed. KIR2DS4 is believed to recognize HLA-C*1601 (C1), HLA-C*0501 (C2), and HLA-A*1102 (Graef et al. 2009). To date, KIR2DS3, KIR2DS5, and KIR2DL5 have no known ligands.

A unique feature of KIR and Ly49 receptors is their stochastic distribution across the NK cell population (Anderson 2006; Uhrberg 2005). In combination with genetic variability of the KIR/Ly49 locus at the levels of gene content, copy number variation, and allelic polymorphism, the stochastic expression of the KIR gene products results in highly diverse NK cell-repertoires among individuals. Unlike the positive and negative selection of T cells in the thymus, there is no intrinsic selection process that delete NK cells that lack inhibitory receptors to self HLA class I (Andersson et al. 2009). However, most KIR/Ly49-negative NK cells express CD94/NKG2A, an inhibitory receptor that binds to the ubiquitously expressed HLA-E molecule (in humans) and Qa1 (in mice) (Andersson et al. 2009; Braud et al. 1998; Vance et al. 1998; Veinotte et al. 2003; Yawata et al. 2008). The inverse correlation between strong KIR-HLA alleles and HLA alleles that favor functional NKG2A/HLA-E interactions is a striking example of complementary evolution (Horowitz et al. 2016). The intuitive function of these complementary inhibitory receptor-ligand pairs is to preserve tolerance to self by limiting autoreactivity against tissues with expression of self-HLA class I. The expression of self-inhibitory receptors is tightly linked to the ability of NK cells to gain functional potential during a process termed education (Anfossi et al. 2006). Consequently, NK cells that lack self-specific inhibitory receptors, approximately 10% of all NK cells in both mice and humans, are hyporesponsive (Fauriat et al. 2008; Fernandez et al. 2005). In the next section, we discuss how this functional calibration against self-MHC class I allows NK cells to sense the loss of MHC class I on target cells.

Calibration of “missing self” reactivity through MHC class I recognition

In recent years, it has become clear that inhibitory receptors not only abrogate functional responses in NK cells during the effector phase, but also tune the cell-intrinsic functional potential during homeostatic conditions. Thus, inhibitory interactions with self-MHC class I translate into a quantitative relationship between self-recognition and effector function. Paradoxically, NK cells expressing self-MHC class I specific inhibitory receptors, receiving constitutive inhibitory input, exhibit gained functionality, including cytokine production and killing activity. This functional calibration against self-MHC class I is critical for the ability of NK cells to recognize and kill target cells displaying reduced MHC class I expression.

NK cell education can be observed at the population level by challenging the NK cells with various stimuli. All NK cell effector functions, from the most proximal Ca-flux, adhesion and formation of the immune synapse, induction and secretion of cytokines/chemokines, exocytosis of cytolytic granules all the way to in vivo killing of MHC class I-mismatched targets can be linked to the educational status of the NK cell (Anfossi et al. 2006; Guia et al. 2011; Thomas et al. 2013; Tu et al. 2014). Mouse models have demonstrated that the functional phenotype induced by education is dynamic and dependent on the net signaling input to NK cells from hematopoietic cells and to some extent from stromal cells (Ebihara et al. 2013). Previous experiments have shown that transfer of mature NK cells from one MHC class I environment to another results in reshaping of the functional potential based on the inhibitory input in the new MHC class I setting (Ebihara et al. 2013; Elliott et al. 2010). Genetic knockdown of SLAM-family receptors by CRISPR/Cas9 induces hyperfunctionality (Chen et al. 2016), whereas deletion of the inhibitory signaling through ITIM and SHP-1 renders NK cells hypofunctional (Kim et al. 2005; Viant et al. 2014). These results highlight the important role of cell-to-cell communication in the regulation of NK cell function. However, it still remains unclear how the net signaling input through activating and inhibitory receptors during education translates into a given functional potential of the cell.

The continuous calibration of the cytotoxic potential serves to maintain tolerance at steady state and determines the response of the individual cell to sudden changes in the environment (i.e., discontinuity) (Pradeu et al. 2013). According to the discontinuity theory of immunity, the immune system is geared to detect sudden changes in the host (Pradeu et al. 2013). In this context, education provides the cell with a capability of detecting discontinuity, such as the loss of MHC-class I ligands, or as we shall discuss next, to mediate alloreactivity upon adoptive transfer to a new HLA class I environment in settings of human transplantation.

Transfer of NK cells across HLA barriers—missing the “new” self MHC class I

Transfer of NK cells across HLA class I barriers can release the cytotoxic potential of a functional repertoire that is otherwise restrained by interactions with self HLA class I molecules in the donor (Ruggeri et al. 1999; Valiante et al. 1997; Yawata et al. 2008). Hence, educated NK cells can sense “missing self” in a new HLA class I environment. This scenario occurs in certain specific donor-recipient combinations in the context of partially mismatched allogeneic hematopoietic stem cell transplantation (HSCT) and has been linked to improved survival (Giebel et al. 2003; Miller et al. 2007; Ruggeri et al. 2002; Symons et al. 2010). For such an NK cell-mediated graft-versus-leukemia (GVL) effect to take place, the recipient must lack any one of the three major KIR-ligands present in the donor.

Notably, most adoptive NK cell trials conducted until now in cancer patients have been based on transfer of polyclonal NK cells across HLA class I barriers, with the aim of eliciting reactivity towards “missing” HLA class I ligands in the new hematopoietic environment (the latter representing the “new self”). However, in many of these studies it has been difficult to attribute the clinical efficacy to the KIR/HLA genetics of the donors (Miller et al. 2005). One possible explanation for this outcome is that most currently used NK cell products contain a limited proportion of alloreactive NK cells, despite a genetically predicted KIR-HLA mismatch (Fauriat et al. 2008). Indeed, the size of the alloreactive repertoire determine the ability of allogeneic NK cells to kill mismatched tumor cells (Pende et al. 2009), and was recently shown to influence clinical outcomes in terms of induction of molecular remission and prolonged disease-free survival in AML (Curti et al. 2016). New insights into the functional diversification of NK cells hold promise for the next generation NK cell therapy based on selective expansion or directed differentiation of specific cell populations with enhanced tumor-killing capacity.

Adaptive NK cells—“missing self” unleashed

As stated above, a variety of different NK cell-based products have been infused to patients with cancer (in particular leukemia) to achieve tumor eradication or reduction (reviewed in ref. (Knorr et al. 2014)). In this context, significant interest has been drawn more recently to the utilization of a specific subpopulation of terminally differentiated NK cells, often referred to as “adaptive” (or memory) NK cells (Liu et al. 2015). Adaptive NK cells, expressing the cell surface receptor NKG2C, are found at varying frequencies in a fraction of CMV seropositive donors. These cells can be efficiently expanded in vitro by stimulation with IL-15 together with feeder cells overexpressing HLA-E (Beziat et al. 2013). Different approaches to expand such adaptive NK cells were recently reviewed by Liu and collaborators (Liu et al. 2015). A unique feature of this NK cell subset is the expression of one single self-HLA class I specific KIR. Noteworthy, such single KIR+ adaptive NK cells may represent up to 75% of all NK cells in some healthy donors (Beziat et al. 2013). Thus, transfer of adaptive NK cells across HLA class I-barriers represents a way to maximize the effects of a “missing self” response. As noted, adaptive NK cells typically express NKG2C and are also negative for NKG2A and are therefore particularly attractive as effector cells also against tumor cells that overexpress HLA-E, either spontaneously or as a result of immune escape (Gooden et al. 2011). Thus, although adaptive NK cells have so far only been shown to expand in response to infection it may be possible to harness their unique properties in cell therapy settings against human cancer.

In support of the notion above, culture of polyclonal NK cells in IL-15 together with feeder cells transfected with HLA-E for 14 days led to an enrichment of adaptive NK cells with distinct KIR specificities that were determined by the HLA-C1/C2 genotype of the donor (Liu et al. 2017). The ex vivo expanded adaptive NK cells gradually obtained a more differentiated phenotype and displayed efficient killing of HLA class I-mismatched T and precursor B cell acute lymphoblastic leukemia (ALL) blasts, previously shown to be refractory to NK cell killing. Selective expansion of NK cells that express one single inhibitory KIR for self-HLA class I would allow exploitation of the full potential of the “missing self” response in cancer immunotherapy across HLA class I barriers.

The most immediate setting for clinical implementation is to transfer ex vivo expanded adaptive NK cells across HLA-C barriers (Fig. 1a). In such protocols, cells generated from a C1/C1 donor could be transferred to patients with C2/C2 genotypes and vice versa. Notably, C1/C2 donors could also be used pending on their CMV-imprinted repertoire. In C1/C2 donors with a pre-existing expansion of 2DL1+ adaptive NK cells, it could be possible to further expand such cells, extending the number of available donors for C1/C1 patients (Liu et al. 2017), which may be of clinical relevance given that the C2/C2 genotype is rather rare.
Fig. 1

Exploiting “missing self” reactivity against HLA class I mismatched or deficient tumor targets. A schematic illustration of the conceptual basis for the usage of adaptive single-KIR+ NK cells in clinical cell therapy settings. a By selectively expanding NK cells expressing, for example, KIR2DL3 as their only inhibitory KIR, the potential for “missing self” recognition can be amplified when these cells are transferred across HLA class I barriers, to a recipient lacking the HLA-C1 molecule. The specific targeting of tumor cells relies on induced expression of ligands (PVR and MICA) binding to activating receptors DNAM-1 and NKG2D, respectively. Likewise adaptive NK cells express high levels of CD2 that may contribute to target cell recognition of cells that express CD58. It remains an open question whether effector function will be down-tuned in the new MHC class I environment due to the absence of self HLA class I on all recipient cells. b Adaptive NK cells can also be used against tumors displaying spontaneous or therapy-induced loss of HLA class I molecules. If autologous or HLA class I matched allogeneic NK cells are used as a source to differentiate/selectively expand the adaptive NK cell population, normal tissue will be spared. There is also the possibility of maintained education of adaptive NK cells against self HLA class I expressed by normal cells

However, we foresee that adaptive NK cells may also be used to fully explore the clinical potential of “missing self” recognition in the context of partial or total HLA class I loss, either spontaneous or induced by T cell-based cancer immunotherapy. Specifically, as we shall discuss in the next section, NK cell-based strategies may hold promise as a rescue therapy for patients that acquire resistance to tumor-specific CD8 T cells, and hence also checkpoint inhibition, due to loss of HLA class I expression.

Natural and acquired resistance to cytotoxic T cells

A consequence of immune-mediated tumor recognition is a continuous “sculpturing” of the tumor phenotype, referred to as immunoediting (Schreiber et al. 2011). The immune selection pressure favors the development of less immunogenic tumors, which escape recognition by a functioning immune system. Presentation of antigens in the context of HLA class I molecules is critical for CD8 T cell priming, and during the effector phase of an adaptive immune response. Alterations in antigen processing and presentation are commonly seen both during viral infection and in malignancies.

Viruses have adapted to the immune-mediated selection pressure in numerous ingenious ways, affecting almost every part of the MHC class I presentation pathway (Yewdell and Hill 2002). In tumors, the antigen presentation pathway can be disrupted as a consequence of mutations and/or deletions of one or several genes encoding components of the antigen presentation machinery. Complete loss of HLA class I molecules is a common event in several murine and human tumors including melanoma, diffuse large cell B cell lymphoma (DLBCL), cervical, lung, prostate, and renal cell carcinoma (Garrido et al. 2016; Khong and Restifo 2002). In fact, loss of HLA class I has been reported in up to 80% of non-small cell lung cancer and 50% of DLBCL (Bukur et al. 2012). A survey of several melanoma cell lines revealed little or no expression of genes of the HLA-C locus (Marincola et al. 1994). Since the MHC class I molecule is not properly assembled in the absence of peptide and/or β2m (Ljunggren et al. 1990a), loss of HLA class I may depend on alteration of β2m expression or mutations of proteasomal subunits as well as of transporters associated with antigen presentation (TAP1/2) (Seliger et al. 2002).

Tumors may also often display a selective loss of HLA-haplotype, locus or allele. Haplotype losses may be the result of loss of heterozygocity (LOH) on chromosome 6 (Ramal et al. 2000). In addition to these irreversible mechanisms underlying loss of HLA class I, there are a number of reversible (“soft”) causes of low HLA class I expression that may possibly be manipulated through immune interventions to achieve tumor rejection (Garrido et al. 2017). In DLBLC, 29% of the cases displayed mutations and deletions of the β2m gene (Challa-Malladi et al. 2011). However, additional soft mechanisms led to aberrant expression of HLA class I in more than 60% of all analyzed cases. Intriguingly, the gradual loss of HLA class I during tumor progression appears to be paralleled with exclusion of T cell infiltrates, suggesting a tight interplay between immune recognition and structural organization of the tumor tissue (Garrido et al. 2017).

Loss of HLA class I may also occur as a result of ongoing immunotherapy. Sequential loss of several HLA class I alleles in successive metastases from a patient undergoing immunotherapy suggests that immune mediated selection pressure plays a pivotal role in selecting HLA class I loss variants (Lehmann et al. 1995). β2m mutations along with LOH of the second allele have been described during adoptive immunotherapy (Restifo et al. 1996; Sucker et al. 2014). Therapy-induced loss of HLA class I due to an acquired point mutation in β2m has also been described to lead to resistance to tumor specific CD8 T cells despite retained antigen expression (Rosenberg et al. 2003).

Immunotherapy with checkpoint inhibition, such as anti-programmed death 1 (PD-1) or anti-CTLA-4, has led to a paradigm shift in cancer treatment. Tumor infiltrating CD8 T cells are the main effector cells that kill cancer cells during PD-1 blockade therapy (Tumeh et al. 2014). Most objective responses to anti-PD-1 and anti-CTLA-4 are durable (Hamid et al. 2013; Prieto et al. 2012; Schadendorf et al. 2015). However, in one study approximately 25% of patients with melanoma who had an objective response to PD-1 blockade therapy had disease progression at a median follow-up of 21 months (Ribas et al. 2016). Acquired resistance to anti-PD-1 therapy has been associated with alterations in the antigen presentation pathway (Zaretsky et al. 2016). Whole exome sequencing in four patients with relapsing metastatic melanoma revealed clonal selection and outgrowth resistant tumors with loss-of-function mutations in the genes encoding interferon-receptor-associated Janus kinase 1 (JAK1) or Janus kinase (JAK2), together with deletion of the wild-type allele in two patients (Zaretsky et al. 2016). A third patient displayed a truncating mutation in the β2m gene, associated with a complete loss of HLA class I at the surface. Although these resistance mechanisms were so far only identified in a limited number of patients, the fact that three of four patients with acquired resistance to immunotherapy displayed alterations in the antigen presentation machinery suggests that this may be a common mechanism. Furthermore, given the frequent loss of HLA class I in a wide range of tumor samples, it is tempting to speculate that alterations in the antigen presentation pathway are implicated also in the primary resistance to checkpoint inhibition. Ongoing efforts to decipher mechanisms of resistance will be helpful in determining if some of these patients may instead be targeted by NK cell-based immunotherapies.

The search for missing self—30 years later

Since NK cells specifically sense the absence of HLA class I, adoptive NK cell therapy may be an attractive rescue option for patients that fail conventional immunotherapy or in an upfront setting for patients with tumors displaying low levels of HLA class I at diagnosis. Indeed, loss of β2m leads to increased NK sensitivity and effective tumor elimination by NK cells (Glas et al. 1992). Although one could theoretically use autologous NK cells in these contexts, unmanipulated autologous NK cells express highly diverse KIR repertoires and may often be functionally suppressed (Carlsten et al. 2010; Malmberg and Ljunggren 2006). An advantage of adaptive NK cells is their predictable and homogenous expression of self-KIR rendering this highly cytolytic subset completely tolerant to normal tissues (Fig. 1b). Furthermore, adaptive NK cells display potential for long-term persistence, possibly even self-renewal (Beziat et al. 2013; Corat et al. 2017; Schlums et al. 2017), and could therefore achieve long-term engraftment, even in the absence of conditioning.

Nevertheless, there are several bottlenecks that need to be addressed for the successful clinical implementation of next generation NK cell strategies. First, we have limited insights into the mechanisms that regulate homing of NK cells to the tumor. Patient-derived NK cells are rarely found in tumors and often display a naïve CD56bright phenotype (Carrega et al. 2008; Del Mar Valenzuela-Membrives et al. 2016). Second, experimental models in mice suggest that NK cells down-tune their functional potential within 48 h following transfer to a new environment (Joncker et al. 2010). Third, additional genetic alterations in the tumor may impede immune cell recognition. For example, a large fraction of DLBCL cases display genetic inactivation of CD58, which is the ligand for the co-activation receptor and adhesion molecule CD2 (Challa-Malladi et al. 2011). CD2 is critical for both T and NK cell adhesion to the target and subsequent activation (Bolhuis et al. 1986; Kanner et al. 1992; Wang et al. 1999). Despite these hurdles, we believe that NK cell recognition of “missing self” is likely more clinically relevant than ever before and may hold promise to convert immune failures into clinical responders. New insights into the mechanisms that determine the dynamic tuning of NK cells during education may provide means to manipulate NK cell function to help maintain the functional potential of alloreactive NK cells in vivo. NK cells may also be engineered to express chimeric antigen receptors for enhanced targeting and/or to express adhesion molecules or homing receptors.


Compliance with ethical standards

Conflicts of interest

K.J. Malmberg serves on the Scientific Advisory Board of Fate Therapeutics. H.G. Ljunggren serves on the Scientific Advisory Board of CellProtect Nordic Pharmaceuticals and HOPE Bio-Sciences; on the Board of Directors of Vycellix; and is a collaborator with Fate Therapeutics. The respective relationships have been reviewed and managed by Oslo University Hospital and Karolinska Institutet in accordance with the institutions’ conflict of interest polices.

Grant support

This work was supported by grants from the Swedish Research Council, the Swedish Children’s Cancer Society, the Swedish Cancer Society, the Karolinska Institutet, the Norwegian Cancer Society, the Norwegian Research Council, the South-Eastern Norway Regional Health Authority, and the KG Jebsen Center for Cancer Immunotherapy.


  1. Anderson SK (2006) Transcriptional regulation of NK cell receptors. Curr Top Microbiol Immunol 298:59–75PubMedGoogle Scholar
  2. Andersson S, Fauriat C, Malmberg JA, Ljunggren HG, Malmberg KJ (2009) KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression. Blood 114:95–104CrossRefPubMedGoogle Scholar
  3. Anfossi N, Andre P, Guia S, Falk CS, Roetynck S, Stewart CA, Breso V, Frassati C, Reviron D, Middleton D, Romagne F, Ugolini S, Vivier E (2006) Human NK cell education by inhibitory receptors for MHC class I. Immunity 25:331–342CrossRefPubMedGoogle Scholar
  4. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727–729CrossRefPubMedGoogle Scholar
  5. Beziat V, Liu LL, Malmberg JA, Ivarsson MA, Sohlberg E, Bjorklund AT, Retiere C, Sverremark-Ekstrom E, Traherne J, Ljungman P, Schaffer M, Price DA, Trowsdale J, Michaelsson J, Ljunggren HG, Malmberg KJ (2013) NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood 121:2678–2688CrossRefPubMedPubMedCentralGoogle Scholar
  6. Biassoni R, Pessino A, Malaspina A, Cantoni C, Bottino C, Sivori S, Moretta L, Moretta A (1997) Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur J Immunol 27:3095–3099CrossRefPubMedGoogle Scholar
  7. Bolhuis RL, Roozemond RC, van de Griend RJ (1986) Induction and blocking of cytolysis in CD2+, CD3- NK and CD2+, CD3+ cytotoxic T lymphocytes via CD2 50 KD sheep erythrocyte receptor. J Immunol 136:3939–3944PubMedGoogle Scholar
  8. Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, Lanier LL, McMichael AJ (1998) HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391:795–799CrossRefPubMedGoogle Scholar
  9. Bryceson YT, March ME, Ljunggren HG, Long EO (2006) Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 214:73–91CrossRefPubMedGoogle Scholar
  10. Bukur J, Jasinski S, Seliger B (2012) The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol 22:350–358CrossRefPubMedGoogle Scholar
  11. Carlsten M, Baumann BC, Simonsson M, Jadersten M, Forsblom AM, Hammarstedt C, Bryceson YT, Ljunggren HG, Hellstrom-Lindberg E, Malmberg KJ (2010) Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome. Leukemia 24:1607–1616CrossRefPubMedGoogle Scholar
  12. Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, Ratto GB, Mingari MC, Moretta L, Ferlazzo G (2008) Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56bright CD16 cells and display an impaired capability to kill tumor cells. Cancer 112:863–875CrossRefPubMedGoogle Scholar
  13. Challa-Malladi M, Lieu YK, Califano O, Holmes AB, Bhagat G, Murty VV, Dominguez-Sola D, Pasqualucci L, Dalla-Favera R (2011) Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 20:728–740CrossRefPubMedPubMedCentralGoogle Scholar
  14. Chen S, Yang M, Du J, Li D, Li Z, Cai C, Ma Y, Zhang L, Tian Z, Dong Z (2016) The self-specific activation receptor SLAM family is critical for NK cell education. Immunity 45:292–304CrossRefPubMedGoogle Scholar
  15. Corat MA, Schlums H, Wu C, Theorell J, Espinoza DA, Sellers SE, Townsley DM, Young NS, Bryceson YT, Dunbar CE, Winkler T (2017) Acquired somatic mutations in PNH reveal long-term maintenance of adaptive NK cells independent of HSPCs. Blood 129:1940–1946CrossRefPubMedGoogle Scholar
  16. Cudkowicz G, Stimpfling JH (1964) Induction of immunity and of unresponsiveness to parental marrow grafts in adult F-1 hybrid mice. Nature 204:450–453CrossRefPubMedGoogle Scholar
  17. Curti A, Ruggeri L, Parisi S, Bontadini A, Dan E, Motta MR, Rizzi S, Trabanelli S, Ocadlikova D, Lecciso M, Giudice V, Fruet F, Urbani E, Papayannidis C, Martinelli G, Bandini G, Bonifazi F, Lewis RE, Cavo M, Velardi A, Lemoli RM (2016) Larger size of donor Alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients. Clin Cancer Res 22:1914–1921CrossRefPubMedGoogle Scholar
  18. Del Mar Valenzuela-Membrives M, Perea-Garcia F, Sanchez-Palencia A, Ruiz-Cabello F, Gomez-Morales M, Miranda-Leon MT, Galindo-Angel I, Farez-Vidal ME (2016) Progressive changes in composition of lymphocytes in lung tissues from patients with non-small-cell lung cancer. Oncotarget 7:71608–71619PubMedPubMedCentralGoogle Scholar
  19. Ebihara T, Jonsson AH, Yokoyama WM (2013) Natural killer cell licensing in mice with inducible expression of MHC class I. Proc Natl Acad Sci U S A 110:E4232–E4237CrossRefPubMedPubMedCentralGoogle Scholar
  20. Elliott JM, Wahle JA, Yokoyama WM (2010) MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J Exp Med 207:2073–2079CrossRefPubMedPubMedCentralGoogle Scholar
  21. Fauriat C, Andersson S, Bjorklund AT, Carlsten M, Schaffer M, Bjorkstrom NK, Baumann BC, Michaelsson J, Ljunggren HG, Malmberg KJ (2008) Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group a KIR haplotype. J Immunol 181:6010–6019CrossRefPubMedGoogle Scholar
  22. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH (2005) A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 105:4416–4423CrossRefPubMedPubMedCentralGoogle Scholar
  23. Gardiner CM, Guethlein LA, Shilling HG, Pando M, Carr WH, Rajalingam R, Vilches C, Parham P (2001) Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J Immunol 166:2992–3001CrossRefPubMedGoogle Scholar
  24. Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T (2016) The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol 39:44–51CrossRefPubMedPubMedCentralGoogle Scholar
  25. Garrido F, Perea F, Bernal M, Sanchez-Palencia A, Aptsiauri N, Ruiz-Cabello F (2017) The escape of cancer from T cell-mediated immune surveillance: HLA class I loss and tumor tissue architecture. Vaccines (Basel) 5Google Scholar
  26. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, Maccario R, Bonetti F, Wojnar J, Martinetti M, Frassoni F, Giorgiani G, Bacigalupo A, Holowiecki J (2003) Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102:814–819CrossRefPubMedGoogle Scholar
  27. Glas R, Sturmhofel K, Hammerling GJ, Karre K, Ljunggren HG (1992) Restoration of a tumorigenic phenotype by beta 2-microglobulin transfection to EL-4 mutant cells. J Exp Med 175:843–846CrossRefPubMedGoogle Scholar
  28. Gooden M, Lampen M, Jordanova ES, Leffers N, Trimbos JB, van der Burg SH, Nijman H, van Hall T (2011) HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8(+) T lymphocytes. Proc Natl Acad Sci U S A 108:10656–10661CrossRefPubMedPubMedCentralGoogle Scholar
  29. Goodridge JP, Burian A, Lee N, Geraghty DE (2013) HLA-F and MHC class I open conformers are ligands for NK cell Ig-like receptors. J Immunol 191:3553–3562CrossRefPubMedPubMedCentralGoogle Scholar
  30. Graef T, Moesta AK, Norman PJ, Abi-Rached L, Vago L, Older Aguilar AM, Gleimer M, Hammond JA, Guethlein LA, Bushnell DA, Robinson PJ, Parham P (2009) KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. J Exp Med 206:2557–2572CrossRefPubMedPubMedCentralGoogle Scholar
  31. Guia S, Jaeger BN, Piatek S, Mailfert S, Trombik T, Fenis A, Chevrier N, Walzer T, Kerdiles YM, Marguet D, Vivier E, Ugolini S (2011) Confinement of activating receptors at the plasma membrane controls natural killer cell tolerance. Sci Signal 4:ra21CrossRefPubMedGoogle Scholar
  32. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144CrossRefPubMedPubMedCentralGoogle Scholar
  33. Hoglund P, Ohlen C, Carbone E, Franksson L, Ljunggren HG, Latour A, Koller B, Karre K (1991) Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m- mice: nonresponsiveness controlled by beta 2m- bone marrow in chimeric mice. Proc Natl Acad Sci U S A 88:10332–10336CrossRefPubMedPubMedCentralGoogle Scholar
  34. Horowitz A, Djaoud Z, Nemat-Gorgani N, Blokhuis J, Hilton HG, Beziat V, Malmberg KJ, Norman PJ, Guethlein LA, Parham P (2016) Class I HLA haplotypes form two schools that educate NK cells in different ways. Sci Immunol 1Google Scholar
  35. Joncker NT, Shifrin N, Delebecque F, Raulet DH (2010) Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J Exp Med 207:2065–2072CrossRefPubMedPubMedCentralGoogle Scholar
  36. Kanner SB, Damle NK, Blake J, Aruffo A, Ledbetter JA (1992) CD2/LFA-3 ligation induces phospholipase-C gamma 1 tyrosine phosphorylation and regulates CD3 signaling. J Immunol 148:2023–2029PubMedGoogle Scholar
  37. Karlhofer FM, Ribaudo RK, Yokoyama WM (1992) MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature 358:66–70CrossRefPubMedGoogle Scholar
  38. Karre K (2008) Natural killer cell recognition of missing self. Nat Immunol 9:477–480CrossRefPubMedGoogle Scholar
  39. Karre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319:675–678CrossRefPubMedGoogle Scholar
  40. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3:999–1005CrossRefPubMedPubMedCentralGoogle Scholar
  41. Kiessling R, Hochman PS, Haller O, Shearer GM, Wigzell H, Cudkowicz G (1977) Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts. Eur J Immunol 7:655–663CrossRefPubMedGoogle Scholar
  42. Kiessling R, Klein E, Wigzell H (1975) “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 5:112–117CrossRefPubMedGoogle Scholar
  43. Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, French AR, Sunwoo JB, Lemieux S, Hansen TH, Yokoyama WM (2005) Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436:709–713CrossRefPubMedGoogle Scholar
  44. Knorr DA, Bachanova V, Verneris MR, Miller JS (2014) Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol 26:161–172CrossRefPubMedPubMedCentralGoogle Scholar
  45. Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23:225–274CrossRefPubMedGoogle Scholar
  46. Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG (1995) Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25:340–347CrossRefPubMedGoogle Scholar
  47. Liao NS, Bix M, Zijlstra M, Jaenisch R, Raulet D (1991) MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science 253:199–202CrossRefPubMedGoogle Scholar
  48. Liu LL, Pfefferle A, Yi Sheng VO, Bjorklund AT, Beziat V, Goodridge JP, Malmberg KJ (2015) Harnessing adaptive natural killer cells in cancer immunotherapy. Mol Oncol 9(10):1904–1917Google Scholar
  49. Liu LL, Beziat V, Yi Sheng VO, Pfefferle A, Schaffer M, Lehmann S, Hellstrom-Lindberg E, Soderhall S, Heyman M, Grander D, Malmberg KJ (2017) Ex vivo expanded adaptive NK cells effectively kill primary acute lymphoblastic leukemia cells. American Association for Cancer Research, Philadelphia. doi: 10.1158/2326-6066.CIR-16-0296
  50. Ljunggren HG, Karre K (1985) Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med 162:1745–1759CrossRefPubMedGoogle Scholar
  51. Ljunggren HG, Karre K (1990) In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today 11:237–244CrossRefPubMedGoogle Scholar
  52. Ljunggren HG, Ohlen C, Hoglund P, Yamasaki T, Klein G, Karre K (1988a) Afferent and efferent cellular interactions in natural resistance directed against MHC class I deficient tumor grafts. J Immunol 140:671–678PubMedGoogle Scholar
  53. Ljunggren HG, Paabo S, Cochet M, Kling G, Kourilsky P, Karre K (1989) Molecular analysis of H-2-deficient lymphoma lines. Distinct defects in biosynthesis and association of MHC class I heavy chains and beta 2-microglobulin observed in cells with increased sensitivity to NK cell lysis. J Immunol 142:2911–2917PubMedGoogle Scholar
  54. Ljunggren HG, Stam NJ, Ohlen C, Neefjes JJ, Hoglund P, Heemels MT, Bastin J, Schumacher TN, Townsend A, Karre K et al (1990a) Empty MHC class I molecules come out in the cold. Nature 346:476–480CrossRefPubMedGoogle Scholar
  55. Ljunggren HG, Sturmhofel K, Wolpert E, Hammerling GJ, Karre K (1990b) Transfection of beta 2-microglobulin restores IFN-mediated protection from natural killer cell lysis in YAC-1 lymphoma variants. J Immunol 145:380–386PubMedGoogle Scholar
  56. Ljunggren HG, Yamasaki T, Collins P, Klein G, Karre K (1988b) Selective acceptance of MHC class I-deficient tumor grafts in the brain. J Exp Med 167:730–735CrossRefPubMedGoogle Scholar
  57. Malmberg KJ, Ljunggren HG (2006) Escape from immune- and nonimmune-mediated tumor surveillance. Semin Cancer Biol 16:16–31CrossRefPubMedGoogle Scholar
  58. Marincola FM, Shamamian P, Simonis TB, Abati A, Hackett J, O'Dea T, Fetsch P, Yannelli J, Restifo NP, Mule JJ et al (1994) Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J Immunother Emphasis Tumor Immunol 16:13–23CrossRefPubMedPubMedCentralGoogle Scholar
  59. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, Guethlein LA, Trachtenberg EA, Haagenson M, Horowitz MM, Klein JP, Weisdorf DJ (2007) Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 109:5058–5061CrossRefPubMedPubMedCentralGoogle Scholar
  60. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051–3057CrossRefPubMedGoogle Scholar
  61. Moretta A, Vitale M, Sivori S, Bottino C, Morelli L, Augugliaro R, Barbaresi M, Pende D, Ciccone E, Lopez-Botet M, Moretta L (1994) Human natural killer cell receptors for HLA-class I molecules. Evidence that the Kp43 (CD94) molecule functions as receptor for HLA-B alleles. J Exp Med 180:545–555CrossRefPubMedGoogle Scholar
  62. Parham P (2005a) MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 5:201–214CrossRefPubMedGoogle Scholar
  63. Parham P (2008) The genetic and evolutionary balances in human NK cell receptor diversity. Semin Immunol 20:311–316CrossRefPubMedPubMedCentralGoogle Scholar
  64. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, Romeo E, Cognet C, Martinetti M, Maccario R, Mingari MC, Vivier E, Moretta L, Locatelli F, Moretta A (2009) Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 113:3119–3129CrossRefPubMedGoogle Scholar
  65. Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, Moretta L, Biassoni R, Moretta A (1998) Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 188:953–960CrossRefPubMedPubMedCentralGoogle Scholar
  66. Pradeu T, Jaeger S, Vivier E (2013) The speed of change: towards a discontinuity theory of immunity? Nat Rev Immunol 13:764–769CrossRefPubMedGoogle Scholar
  67. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ (2012) CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18:2039–2047CrossRefPubMedPubMedCentralGoogle Scholar
  68. Ramal LM, Maleno I, Cabrera T, Collado A, Ferron A, Lopez-Nevot MA, Garrido F (2000) Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Hum Immunol 61:1001–1012CrossRefPubMedGoogle Scholar
  69. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA (1996) Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88:100–108CrossRefPubMedPubMedCentralGoogle Scholar
  70. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C (2016) Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315:1600–1609CrossRefPubMedGoogle Scholar
  71. Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, Schwartzentruber DJ, Topalian SL, Restifo NP, Filie A, Chang R, Dudley ME (2003) Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother 26:385–393CrossRefPubMedPubMedCentralGoogle Scholar
  72. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A (1999) Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94:333–339PubMedGoogle Scholar
  73. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097–2100CrossRefPubMedGoogle Scholar
  74. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:1889–1894CrossRefPubMedPubMedCentralGoogle Scholar
  75. Schlums H, Jung M, Han H, Theorell J, Bigley V, Chiang SC, Allan DS, Davidson-Moncada JK, Dickinson RE, Holmes TD, Hsu AP, Townsley D, Winkler T, Wang W, Aukrust P, Nordoy I, Calvo KR, Holland SM, Collin M, Dunbar CE, Bryceson YT (2017) Adaptive NK cells can persist in patients with GATA2 mutation depleted of stem and progenitor cells. Blood 129:1927–1939CrossRefPubMedGoogle Scholar
  76. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570CrossRefPubMedGoogle Scholar
  77. Seliger B, Cabrera T, Garrido F, Ferrone S (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12:3–13CrossRefPubMedGoogle Scholar
  78. Shilling HG, Guethlein LA, Cheng NW, Gardiner CM, Rodriguez R, Tyan D, Parham P (2002) Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. J Immunol 168:2307–2315CrossRefPubMedGoogle Scholar
  79. Stewart CA, Laugier-Anfossi F, Vely F, Saulquin X, Riedmuller J, Tisserant A, Gauthier L, Romagne F, Ferracci G, Arosa FA, Moretta A, Sun PD, Ugolini S, Vivier E (2005) Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A 102:13224–13229CrossRefPubMedPubMedCentralGoogle Scholar
  80. Sucker A, Zhao F, Real B, Heeke C, Bielefeld N, Mabetaen S, Horn S, Moll I, Maltaner R, Horn PA, Schilling B, Sabbatino F, Lennerz V, Kloor M, Ferrone S, Schadendorf D, Falk CS, Griewank K, Paschen A (2014) Genetic evolution of T-cell resistance in the course of melanoma progression. Clin Cancer Res 20:6593–6604CrossRefPubMedGoogle Scholar
  81. Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ (2010) Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol blood marrow transplant 16:533–542CrossRefPubMedGoogle Scholar
  82. Thomas LM, Peterson ME, Long EO (2013) Cutting edge: NK cell licensing modulates adhesion to target cells. J Immunol 191:3981–3985CrossRefPubMedPubMedCentralGoogle Scholar
  83. Traherne JA, Martin M, Ward R, Ohashi M, Pellett F, Gladman D, Middleton D, Carrington M, Trowsdale J (2010) Mechanisms of copy number variation and hybrid gene formation in the KIR immune gene complex. Hum Mol Genet 19:737–751CrossRefPubMedGoogle Scholar
  84. Tu MM, Mahmoud AB, Wight A, Mottashed A, Belanger S, Rahim MM, Abou-Samra E, Makrigiannis AP (2014) Ly49 family receptors are required for cancer immunosurveillance mediated by natural killer cells. Cancer Res 74:3684–3694CrossRefPubMedGoogle Scholar
  85. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–571CrossRefPubMedPubMedCentralGoogle Scholar
  86. Uhrberg M (2005) Shaping the human NK cell repertoire: an epigenetic glance at KIR gene regulation. Mol Immunol 42:471–475CrossRefPubMedGoogle Scholar
  87. Uhrberg M, Parham P, Wernet P (2002) Definition of gene content for nine common group B haplotypes of the Caucasoid population: KIR haplotypes contain between seven and eleven KIR genes. Immunogenetics 54:221–229CrossRefPubMedGoogle Scholar
  88. Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Weidenbach K, Corliss B, Tyan D, Lanier LL, Parham P (1997) Human diversity in killer cell inhibitory receptor genes. Immunity 7:753–763CrossRefPubMedGoogle Scholar
  89. Valiante NM, Uhrberg M, Shilling HG, Lienert-Weidenbach K, Arnett KL, D'Andrea A, Phillips JH, Lanier LL, Parham P (1997) Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7:739–751CrossRefPubMedGoogle Scholar
  90. Vance RE, Kraft JR, Altman JD, Jensen PE, Raulet DH (1998) Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b). J Exp Med 188:1841–1848CrossRefPubMedPubMedCentralGoogle Scholar
  91. Veinotte LL, Wilhelm BT, Mager DL, Takei F (2003) Acquisition of MHC-specific receptors on murine natural killer cells. Crit Rev Immunol 23:251–266CrossRefPubMedGoogle Scholar
  92. Viant C, Fenis A, Chicanne G, Payrastre B, Ugolini S, Vivier E (2014) SHP-1-mediated inhibitory signals promote responsiveness and anti-tumour functions of natural killer cells. Nat Commun 5:5108CrossRefPubMedGoogle Scholar
  93. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A (1998) NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 187:2065–2072CrossRefPubMedPubMedCentralGoogle Scholar
  94. Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati MS, Vitale M, Bottino C, Moretta L, Moretta A, Long EO (1995) Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity 2:439–449CrossRefPubMedGoogle Scholar
  95. Wang JH, Smolyar A, Tan K, Liu JH, Kim M, Sun ZY, Wagner G, Reinherz EL (1999) Structure of a heterophilic adhesion complex between the human CD2 and CD58 (LFA-3) counterreceptors. Cell 97:791–803CrossRefPubMedGoogle Scholar
  96. Wende H, Colonna M, Ziegler A, Volz A (1999) Organization of the leukocyte receptor cluster (LRC) on human chromosome 19q13.4. Mamm Genome 10:154–160CrossRefPubMedGoogle Scholar
  97. Yawata M, Yawata N, Draghi M, Partheniou F, Little AM, Parham P (2008) MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 112:2369–2380CrossRefPubMedPubMedCentralGoogle Scholar
  98. Yewdell JW, Hill AB (2002) Viral interference with antigen presentation. Nat Immunol 3:1019–1025CrossRefPubMedGoogle Scholar
  99. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375(9):819–829. doi: 10.1056/NEJMoa1604958

Copyright information

© The Author(s) 2017

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Karl-Johan Malmberg
    • 1
    • 2
    • 3
    Email author
  • Ebba Sohlberg
    • 3
  • Jodie P. Goodridge
    • 1
    • 2
  • Hans-Gustaf Ljunggren
    • 3
    • 4
  1. 1.Department of Cancer Immunology, Institute for Cancer ResearchOslo University HospitalOsloNorway
  2. 2.The KG Jebsen Centre for Cancer Immunotherapy, Institute of Clinical MedicineUniversity of OsloOsloNorway
  3. 3.Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska InstitutetKarolinska University HospitalStockholmSweden
  4. 4.Cell Therapy InstituteNova Southeastern UniversityFt LauderdaleUSA

Personalised recommendations